The Latest Breaking News on Pharma

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), ANI Pharmaceuticals (ANIP), and United Therapeutics (UTHR). Read more.

CEO Bill Anderson, hired last year to help steer the troubled group in a new direction, ruled out any imminent break-up of the company -- despite mounting pressure from activist investors.

Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.

Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.

The Bench also issued a contempt notice against the company and its Managing Director Acharya Balkrishna for failing to adhere to directions passed in November last year. The “entire country has been taken for a ride”, the Bench said, while reprimanding the Union Government for its failure to take “urgent…

CVS will start filling prescriptions for mifepristone in Massachusetts and Rhode Island. Walgreens will start in New York, Pennsylvania, Massachusetts, California and Illinois.

Biden applauds decision by CVS and Walgreens to offer drug on prescription at stores in several US states where abortion is legal

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.